Evidence map›Paper›PMID 42628528›Full record

ArticleCell reports. Medicine2026

Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series.

Tobias Hegelmaier, Jeremias Motte, Denise Walther, Eugen Feist, Alexander Duscha, Christiane Desel, Vaia Pappa, Martin Böttcher, Marvin Voigt, Melissa Sgodzai and 7 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Tobias HegelmaierDepartment of Neurology and Clinical Neurophysiology, Hannover Medical School, 30625 Hannover, Germany.
Jeremias MotteDepartment of Neurology, St. Josef-Hospital, Ruhr-University Bochum, 44791 Bochum, Germany.
Denise WaltherDepartment of Hematology, Oncology, and Cell Therapy, University Hospital, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany.
Eugen FeistExperimental Rheumatology of the Otto-von-Guericke-University Magdeburg, 39120 Magdeburg, Germany; Helios Fachklinik Vogelsang-Gommern, 39245 Vogelsang-Gommern, Germany.
Alexander DuschaDepartment of Neurology and Clinical Neurophysiology, Hannover Medical School, 30625 Hannover, Germany.
Christiane DeselDepartment of Neurology and Clinical Neurophysiology, Hannover Medical School, 30625 Hannover, Germany.
Vaia PappaDepartment of Neurology and Clinical Neurophysiology, Hannover Medical School, 30625 Hannover, Germany.
Martin BöttcherDepartment of Hematology, Oncology, and Cell Therapy, University Hospital, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany.
Marvin VoigtDepartment of Neurology, St. Josef-Hospital, Ruhr-University Bochum, 44791 Bochum, Germany.
Melissa SgodzaiDepartment of Neurology, St. Josef-Hospital, Ruhr-University Bochum, 44791 Bochum, Germany.
Marwa Al-DubaiDepartment of Neurology, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany.
Roland SchroersDepartment of Haematology and Oncology, Knappschaft Kliniken, Ruhr University Bochum, 44892 Bochum, Germany.
Dominic BorieKyverna Therapeutics, Emeryville, CA 94608, USA.
Georg SchettDepartment of Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University, Erlangen and Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
Dimitrios MougiakakosDepartment of Hematology, Oncology, and Cell Therapy, University Hospital, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany.
Ralf GoldDepartment of Neurology, St. Josef-Hospital, Ruhr-University Bochum, 44791 Bochum, Germany.
Aiden HaghikiaDepartment of Neurology and Clinical Neurophysiology, Hannover Medical School, 30625 Hannover, Germany. Electronic address: haghikia.aiden@mh-hannover.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-CD19 CAR T cell therapy represents an emerging therapeutic approach for generalized, treatment-refractory myasthenia gravis (MG), a predominantly B-cell-mediated autoimmune disease for which durable treatment-free remission remains an unmet clinical goal. Despite recent advances, current targeted therapies generally require lifelong repeated administration and rarely induce durable treatment-free remission. We report on three patients with severe, treatment-resistant MG, including one patient with concomitant rheumatoid arthritis, treated with autologous, fully human anti-CD19 CAR T cells. All three patients achieve rapid, sustained clinical MG remission for at least 19 months, allowing discontinuation of MG-specific immunotherapies and substantial improvement in clinical and functional outcomes despite persistent detectable anti-AChR autoantibody titers. B cell depletion is profound, and treatment-related adverse events remain transient and manageable during long-term follow-up. These data support anti-CD19 CAR T cell therapy as a durable, effective intervention for refractory MG and warrant further evaluation in prospective controlled clinical trials.

Indexed as

Antigens, CD19Immunotherapy, AdoptiveMyasthenia GravisReceptors, Chimeric AntigenT-LymphocytesAdultAgedB-LymphocytesFemaleHumansMaleMiddle AgedTreatment OutcomeAntigens, CD19CD19 molecule, humanReceptors, Chimeric AntigenautoimmunityCAR T cell therapyimmune resetimmunotherapyliving druglong-term remissionneuroimmunological diseaseseropositive refractory myasthenia gravis

Identifiers

PMID42628528
PMCPMC13589498

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.